Noninvasive prediction of Ki-67 expression in pancreatic cancer via contrast-enhanced ultrasound quantitative parameters: A diagnostic model study

被引:0
作者
Yang, Zi-Yi [1 ]
Wan, Wei-Na [1 ]
Zhao, Lei [1 ]
Li, Si-Nong [1 ]
Liu, Zhe [2 ]
Sang, Liang [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Ultrasonog, 155 Nanjing North St, Shenyang 110001, Liaoning, Peoples R China
[2] China Med Univ, Affiliated Hosp 1, Dept Pancreat Biliary Surg, Shenyang 110001, Liaoning, Peoples R China
关键词
Contrast-enhanced ultrasound; Pancreatic cancer; Quantitative analysis; Ki-67; index; Pathological differentiation degree; SURVIVAL; MARKER; INDEX; KI67;
D O I
10.4251/wjgo.v17.i6.107919
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND The expression level of Ki-67 and the degree of differentiation in pancreatic cancer determine tumor aggressiveness and patient prognosis, which holds significant implications for clinical decision-making. A major challenge in preoperative pancreatic ductal adenocarcinoma management is predicting tumor malignancy. Contrast-enhanced ultrasound (CEUS), a dynamic imaging technique based on blood pool visualization, can reveal lesion vasculature and provide quantitative perfusion data reflecting angiogenesis. By tracking contrast agent kinetics, CEUS offers non-invasive insights into tumor vascularization, helping assess malignancy potential. AIM To investigate the correlation between Ki-67 and pancreatic cancer differentiation using CEUS quantitative parameters and evaluated their diagnostic accuracy. METHODS This retrospective study analyzed pancreatic cancer patients who underwent CEUS and pathological confirmation. Pathological differentiation, clinical data, and quantitative CEUS parameters [maximum intensity (IMAX), rise time (RT), rise slope 50% (Rs50), rise slope 10%-90% (Rs1090), etc.] were collected. Based on Ki-67 expression (< 50% vs >= 50%), patients were divided into low- and high-expression groups. The study evaluated correlations between Ki-67 expression, differentiation degree, and CEUS quantitative parameters to assess tumor aggressiveness. RESULTS Among 54 patients (25 high Ki-67, 29 low Ki-67), significant differences (P < 0.05) were observed in Rs50, IMAX, wash-out area under the curve (WoutAUC), wash-in and out area under curve, and Rs1090 between high and low Ki-67 groups. High-expression patients showed elevated Rs50, IMAX, WoutAUC, and area under the curve (AUC), while RT and falling slope 50% (Fs50) were lower. Rs1090 demonstrated the highest diagnostic accuracy (AUC = 0.863, sensitivity = 0.92, specificity = 0.759). Fs50 was effective in low Ki-67 detection (AUC = 0.838). No correlation was found between enhancement patterns and Ki-67 or differentiation. CONCLUSION CEUS parameters (Rs50, IMAX, WoutAUC, Rs1090) strongly correlate with Ki-67, aiding non-invasive pancreatic cancer assessment. Rs1090/IMAX predict high Ki-67; Fs50 identifies low Ki-67, supporting CEUS for tumor aggressiveness evaluation.
引用
收藏
页码:1 / 17
页数:18
相关论文
共 30 条
[1]   Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions [J].
An, Yan-Fei ;
Pu, Ning ;
Jia, Jin-Bin ;
Wang, Wen-Quan ;
Liu, Liang .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (05)
[2]   High microvessel density in pancreatic ductal adenocarcinoma is associated with high grade [J].
Barau, Anca ;
Ruiz-Sauri, Amparo ;
Valencia, Gerardo ;
del Carmen Gomez-Mateo, Maria ;
Sabater, Luis ;
Ferrandez, Antonio ;
Llombart-Bosch, Antonio .
VIRCHOWS ARCHIV, 2013, 462 (05) :541-546
[3]   Qualitative and Quantitative Contrast-enhanced Endoscopic Ultrasound Improves Evaluation of Focal Pancreatic Lesions [J].
Buxbaum, James ;
Ko, Chris ;
Varghese, Nino ;
Lee, Alice ;
Sahakian, Ara ;
King, Kevin ;
Serna, Jessica ;
Lee, Helen ;
Tchelepi, Hisham ;
Van Dam, Jacques ;
Duddalwar, Vinay .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (04) :917-+
[4]   Percutaneous ultrasound and endoscopic ultrasound-guided biopsy of solid pancreatic lesions: An analysis of 1074 lesions [J].
Chai, Wei-Lu ;
Kuang, Xiu-Feng ;
Yu, Li ;
Cheng, Chao ;
Jin, Xin-Yan ;
Zhao, Qi-Yu ;
Jiang, Tian-An .
HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (03) :302-309
[5]   Low-dose X-ray irradiation combined with FAK inhibitors improves the immune microenvironment and confers sensitivity to radiotherapy in pancreatic cancer [J].
Chen, Huanliang ;
Tu, Wenzhi ;
Lu, Yue ;
Zhang, Yingzi ;
Xu, Yiqing ;
Chen, Xuming ;
Zhu, Meiling ;
Liu, Yong .
BIOMEDICINE & PHARMACOTHERAPY, 2022, 151
[6]   Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection [J].
Fahrmann, Johannes F. ;
Schmidt, C. Max ;
Mao, Xiangying ;
Irajizad, Ehsan ;
Loftus, Maureen ;
Zhang, Jinming ;
Patel, Nikul ;
Vykoukal, Jody ;
Dennison, Jennifer B. ;
Long, James P. ;
Do, Kim-Anh ;
Zhang, Jianjun ;
Chabot, John A. ;
Kluger, Michael D. ;
Kastrinos, Fay ;
Brais, Lauren ;
Babic, Ana ;
Jajoo, Kunal ;
Lee, Linda S. ;
Clancy, Thomas E. ;
Ng, Kimmie ;
Bullock, Andrea ;
Genkinger, Jeanine ;
Yip-Schneider, Michele T. ;
Maitra, Anirban ;
Wolpin, Brian M. ;
Hanash, Samir .
GASTROENTEROLOGY, 2021, 160 (04) :1373-+
[7]   Prediction of the Ki-67 marker index in hepatocellular carcinoma based on Dynamic Contrast-Enhanced Ultrasonography with Sonazoid [J].
Huang, Zhe ;
Zhou, PingPing ;
Li, ShanShan ;
Li, Kaiyan .
INSIGHTS INTO IMAGING, 2022, 13 (01)
[8]   Ki67 labeling index: assessment and prognostic role in gastroenteropancreatic neuroendocrine neoplasms [J].
Kloeppel, Guenter ;
La Rosa, Stefano .
VIRCHOWS ARCHIV, 2018, 472 (03) :341-349
[9]   Ki67 is a promising molecular target in the diagnosis of cancer [J].
Li, Lian Tao ;
Jiang, Guan ;
Chen, Qian ;
Zheng, Jun Nian .
MOLECULAR MEDICINE REPORTS, 2015, 11 (03) :1566-1572
[10]   Development of a CT radiomics nomogram for preoperative prediction of Ki-67 index in pancreatic ductal adenocarcinoma: a two-center retrospective study [J].
Li, Qian ;
Song, Zuhua ;
Li, Xiaojiao ;
Zhang, Dan ;
Yu, Jiayi ;
Li, Zongwen ;
Huang, Jie ;
Su, Kai ;
Liu, Qian ;
Zhang, Xiaodi ;
Tang, Zhuoyue .
EUROPEAN RADIOLOGY, 2024, 34 (05) :2934-2943